+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

B-Cell Lymphomas - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019

  • PDF Icon

    Drug Pipelines

  • 150 Pages
  • January 2019
  • Region: Global
  • DelveInsight
  • ID: 4745461

“B-Cell Lymphomas - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019" report provides comprehensive insights about marketed and Phase III products for B-Cell Lymphomas . The report includes information of marketed products including their product description, patent details, forecasted sales till 2021 & API manufacturer details by country.

Global API Manufacturers of Marketed Products for B-Cell Lymphomas

Coverage of API manufacturers for B-Cell Lymphomas marketed products spanning across United States, Europe, China and India. The manufacturers’ details include manufacturers’ name along with their location.

Emerging Phase III products for B-Cell Lymphomas

This report provides a comprehensive understanding of the emerging Phase III therapies for B-Cell Lymphomas which can turn out to be future prospective competitors for the marketed products. It will also put light on the current market trends. Their forecasted global sales are also provided till 2021.


The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by the research team of industry experts.

Secondary information and data has been collected from various printable and non-printable sources like search engines, news websites, government websites, trade journals, white papers, magazines, trade associations, books, industry portals, industry associations and available databases.

  • A review of the marketed products for B-Cell Lymphomas including their description, route of synthesis, regulatory milestones, forecasted sales estimates till 2021 and API manufacturer details.

  • Patent information coverage of the marketed products including the patent number, holder, grant and patent expiry details

  • API manufacturers for the marketed products with location details

  • Emerging Phase III product profiles for B-Cell Lymphomas including product description, developmental activities, licensors & collaborators and chemical information

Reasons to Buy
  • API intelligence for marketed drugs for the indication and gaining insights of API manufacturers

  • Evaluate the marketing status and patent details of products to exploit opportunities for generic drug development

  • Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to the indication

  • Establish a comprehensive understanding of the emerging Phase III products which can be future competitors in this space

Table of Contents

1. Report Introduction

2. B-Cell Lymphomas: Overview
  • Risk Factors

  • Causes

  • Symptoms

  • Pathophysiology

  • Prognosis

  • Diagnosis

  • Treatment

3. Comparative Analysis of Marketed and Emerging Products

4. Marketed Therapies
4.1. Drug 1: Company name
  • Product Description

  • Route of Synthesis

  • Mechanism of Action

  • Pharmacology

  • Pharmacodynamics

  • Pharmacokinetics

  • Adverse Reactions

  • Clinical Trials

  • Regulatory Milestones

  • Product Development Activities

4.1.1 Product Details
  • United States

  • Europe

4.1.2 Global Sales Assessment
  • Historical Global Sales

  • Forecasted Global Sales

4.1.3 Patent Details
Other marketed products in the detailed report…..

5. Emerging Therapies (Phase III)
5.1 Drug Name: Company Name
  • Product Description

  • Research and Development

  • Product Development Activities

5.1.1 Forecasted Global Sales
Other Phase III profiles in the detailed report…..



Consulting Services

About the Publisher

Contact Us